ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.

Leukemia · 2025 · PMC12208880 · PMID 40275070

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In separate studies from the UK Leukemia Research Fund CLL 4 trial, patients with ATM mutations treated with chemotherapy exhibited shorter progression-free survival (PFS) and overall survival (OS) compared to ATM- wildtype patients, though the differences did not reach statistical significance [ 7 , 17 ].

also in 111,027 other papers

highly significantno p-value reported

Notably, del(11q) was a highly significant marker for TTFT, adding similar risk as SF3B1 mutations or TP53 abnormalities.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.